Catalyst Pharmaceuticals Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : Thank you. Morning, Rich and team. Congrats on a great year of progress and thanks for taking our question. I had a question about FirdApps and really the guidance. I'm wondering if Jeff can provide a little bit more color on the new patient ads as well as the low discontinuation rate that you're seeing. And then with regard to guidance for FirdApps, it's fairly narrow, 355 to 360 versus, for example, Agamri which is broader and and I I'm kind of wondering why you have so much precision on the guidance at this at this stage with regard to FirdApps. Thanks.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : Yeah, it is helpful, and I had just one follow-up, and this is more of a strategy question with regard to the deployment of cash. You're building cash nicely in the last year, and I guess I'm thinking about FICOMPA and perhaps revenue being reduced in 206. Is it your plan to try to replace that revenue with another? Effort in epilepsy or are you not so concerned about epilepsy specifically and investing further in that, but what would you like to do in terms of FICOMPA [revs] in 206? Thanks.

Question: Charles Duncan - Cantor Fitzgerald - Analyst : It's helpful. Thank you.

Question: Bobbin - Bank of America - Analyst : Hey guys, this is Bobbin on for Jason. Congrats on the quarter. First question, I wanted to ask you guys what the new indication that you're pursuing with the Agamri is, which we noted on the PR. And then the second question may be on M&A, is the company looking at gene therapy, which has proven challenging for others in biopharma. And just wanted to get your thoughts on, continued efforts towards revenue diversification. Thank you.

Question: Bobbin - Bank of America - Analyst : Yes, that was great. Thank you guys. I really appreciate the help. Sure.

Question: Asim Ranul - Druid Securities - Analyst : Congrats on the quarter and thanks for taking the questions. This is Asim Ranul on for June Lee. Just a question on the gross net. So you mentioned the gross net changed for FirdApps in 2025. How much of a change should we expect from '24, and then, what proportion of FirdApps patients are currently on the 100 mg dose? Thank you.

Question: Asim Ranul - Druid Securities - Analyst : Thank you.

Question: Benjamin Pellu - Citi - Analyst : Hello, this is Benjamin Pellu for Sam. Thanks for taking our questions. Maybe starting with the Agamri, can you speak to the factors that you expect to drive demand for in 2025 and that support your 2025 guidance of $100 million to $110 million? How should we think about the cadence of the launch throughout the year?

Question: Benjamin Pellu - Citi - Analyst : Yeah, that's helpful. Thank you so much. And then maybe, moving over to FirdApps, can you speak to your expectations for revenue contribution from small cell lung cancer patients over 2025? How much growth are you expecting from this segment over the next several quarters?

Question: Benjamin Pellu - Citi - Analyst : Great, thank you so much.

Question: Joe Kansasaro - Piper Sandler - Analyst : Great. Hey everybody, thanks for taking my questions. Maybe first one following up on those recent comments you made, Jeff, on the queuing effect you're seeing in DMD. Wondering if you could elaborate a little bit more on what you mean by the queuing effect and anything you guys can do to shorten the time a patient spends in that queue and maybe somewhat relatedly what you've seen or heard that has sort of led you to make the decision to separate the sales force. FirdApps and Agamri later this year. Thanks and I have maybe a quick follow up.

Question: Joe Kansasaro - Piper Sandler - Analyst : Yeah, that's helpful. Maybe my follow up on FICOMPA. I know historically you guys have said that, the epilepsy market could be resilient to generics. I'm wondering if your your guidance for 2025 factors some of that resiliency in, and I think you alluded to this a little bit, but any new efforts that you'll employ to maybe slow that that erosion trajectory. Thanks.

Question: Joe Kansasaro - Piper Sandler - Analyst : Great, thank you. Appreciate you circling back on that. Thanks for taking my questions.

Question: Joel Beattie - Bayer - Analyst : Hi, thanks for taking the questions. The first one is related to a Agamri in a competitive DMD marketplace. What are you seeing in terms of the generic erosion for [MFplaza] and how much could that impact the opportunity for Agamri to grow?

Question: Joel Beattie - Bayer - Analyst : Yeah, that does make sense. Thank you. And then maybe one last question related to SGNA in 2025 in the prepared remarks you mentioned an increase this coming year. Could you quantify that at all?

Question: Joel Beattie - Bayer - Analyst : Makes sense. Thank you.

Question: Rowan - Oppenheimer - Analyst : [Hey Leeland. Hey, this] is Rowan on for Leland. Thanks for your question. [How are you doing?] Good. How are you? Just a couple questions for me. Now that we have greater clarity on the FirdApps IP protections moving forward, how does that shape further investment into the franchise and also how do you think about the extended commercial runway and how it changes the approach to business development when evaluating different size and structured deals.

Question: Rowan - Oppenheimer - Analyst : Got it. And we saw that the guidance for FICOMPA reflects some expectations of possible generic erosion. I mean, in patients in the states tend to see greater brand adherence than in others, and can you speak about maybe what you're seeing commercially that is driving the lower guidance?

Question: Rowan - Oppenheimer - Analyst : Thank you. Congrats on another great quarter. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 27, 2025 / 1:30PM, CPRX.OQ - Q4 2024 Catalyst Pharmaceuticals Inc Earnings Call